Department of cardiology, centre hospitalier de Haguenau, 64, avenue du Pr Leriche, 67504 Haguenau cedex, France.
Arch Cardiovasc Dis. 2011 Feb;104(2):89-96. doi: 10.1016/j.acvd.2010.11.006. Epub 2011 Jan 22.
The prognosis for patients aged over 75 years who receive a pacemaker in the context of sinus node dysfunction is unclear.
We sought to evaluate the incidences of atrial fibrillation, heart failure and death in such patients, and the role of the pacing mode in their prognosis.
This was a retrospective study of 102 patients aged over 75 years (mean 82.2 ± 4.4 years) who received a pacemaker in the context of sinus node dysfunction.
During the follow-up period (mean 806 days), 36 patients (35.3%) experienced heart failure, 47 patients (46.1%) had an episode of paroxysmal atrial fibrillation, 19 patients (18.6%) progressed to chronic atrial fibrillation and 29 (28.4%) died, the fatal event being sudden death or of cardiac origin in almost half of these patients (44.8%). Patients assigned to dual-chamber minimal ventricular pacing showed significantly lower rates of heart failure episodes (P=0.023) and all-cause mortality (P<0.001) than those assigned to conventional dual-chamber pacing. In contrast, the two groups did not differ with regard to either paroxysmal or chronic atrial fibrillation.
In patients aged over 75 years, the use of dual-chamber pacemakers incorporating an algorithm minimizing ventricular pacing for sinus node dysfunction seems to decrease the number of heart failure episodes and mortality. On the basis of this finding, the implantation of such devices seems justifiable, even in this age group.
对于因窦房结功能障碍而接受起搏器治疗的 75 岁以上患者,其预后尚不清楚。
我们旨在评估此类患者心房颤动、心力衰竭和死亡的发生率,以及起搏模式在其预后中的作用。
这是一项回顾性研究,共纳入 102 名年龄超过 75 岁(平均 82.2±4.4 岁)的因窦房结功能障碍而接受起搏器治疗的患者。
在随访期间(平均 806 天),36 名患者(35.3%)发生心力衰竭,47 名患者(46.1%)出现阵发性心房颤动,19 名患者(18.6%)进展为慢性心房颤动,29 名患者(28.4%)死亡,其中近一半(44.8%)患者的死亡事件为猝死或心源性。与接受传统双腔起搏的患者相比,被分配至双腔最小心室起搏的患者心力衰竭发作(P=0.023)和全因死亡率(P<0.001)显著降低。然而,两组在阵发性或慢性心房颤动方面没有差异。
对于 75 岁以上的患者,使用双腔起搏器并结合最小化心室起搏的算法治疗窦房结功能障碍似乎可以减少心力衰竭发作次数和死亡率。基于这一发现,即使在这个年龄组,植入此类设备似乎也是合理的。